uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Treatment of macular edema associated with retinal vein occlusion using sustained-release dexamethasone implants in a clinical setting
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Ophthalmology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Ophthalmology.
2013 (English)In: European Journal of Ophthalmology, ISSN 1120-6721, Vol. 23, no 4, 558-563 p.Article in journal (Refereed) Published
Abstract [en]

Purpose: To evaluate the clinical effect, safety, and administration procedure of slow-release dexamethasone implants (Ozurdex (R)) for macular edema secondary to retinal vein occlusion in clinical praxis. Methods: Data from 11 patients (4 eyes with central vein occlusion and 7 eyes with branch vein occlusion) were reviewed. Data were compiled and analyzed with respect to best-corrected visual acuity (BCVA), central macular thickness (CMT), intraocular pressure (IOP), and adverse events. Follow-up was 10 months. Changes in BCVA >= logMAR 0.2, IOP >= 5 mm Hg, and CMT >= 100 mu m were considered clinically relevant. Results: Two months after the first dexamethasone implant, BCVA improved from logMAR 0.65 +/- 0.2 to logMAR 0.34 +/- 0.1. All patients demonstrated a decrease in CMT from an initial average value of 632 +/- 178 mu m to 229 +/- 34 mu m. However, in 10 out of 11 eyes, macular edema recurred by month 4 through 5 and a second dexamethasone implant was administered. Two and 4 months after the second implant, BCVA was logMAR 0.36 +/- 0.2 and logMAR 0.40 +/- 0.2 and the CMT was 254 +/- 61 mu m and 357 +/- 81 mu m, respectively. The IOP increased 5.1 +/- 1.5 mm Hg 1 month after the first implant compared to baseline. In eyes with an IOP above 25 mm Hg (4 out of 11), pressure-lowering eyedrops were administered. Conclusions: Administration of dexamethasone implants induced a clinically relevant increase in visual acuity and a decrease in central macular thickness. In 91% of patients, macular edema recurred within 5 months and a second implant was administered. Adverse events, primarily increased IOP, were manageable. The injection procedure was relatively simple and uncomplicated.

Place, publisher, year, edition, pages
2013. Vol. 23, no 4, 558-563 p.
Keyword [en]
Dexamethasone implant, Intraocular pressure, Ischemia, Ozurdex, Steroids, Vascular endothelial growth factor
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-209180DOI: 10.5301/ejo.5000261ISI: 000324152400015OAI: oai:DiVA.org:uu-209180DiVA: diva2:656154
Available from: 2013-10-15 Created: 2013-10-15 Last updated: 2013-10-15Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Merkoudis, NikolaosGranstam, Elisabet
By organisation
In the same journal
European Journal of Ophthalmology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 185 hits
ReferencesLink to record
Permanent link

Direct link